Odonate (ODTC) Stock Price

Odonate Price

OTC·CLOSED
50,000.00
​
Market closed

Odonate stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Odonate business model & stock analysis

Odonate Therapeutics, Inc. develops therapeutics to improve and extend the lives of patients with cancer, focusing on tesetaxel, a novel chemotherapy agent. Tesetaxel is administered orally with a low pill burden and a simplified dosing regimen, targeting metastatic breast cancer (MBC) patients. The company completed Phase-II studies in MBC, leveraging taxanes that destroy cancer cells by preventing mitosis and inducing apoptosis. Odonate's primary product, tesetaxel, is designed to offer a more convenient treatment option for cancer patients. The company's revenue model centers on the development and potential commercialization of tesetaxel, targeting healthcare providers and oncology practices that treat metastatic breast cancer. Odonate's focus on oral chemotherapy agents with reduced dosing complexity positions it to address unmet needs in cancer therapy, particularly for patients requiring long-term treatment regimens. The firm's pipeline includes tesetaxel as its lead candidate, with no other products or brands mentioned in the business description. Odonate Therapeutics operates as a pharmaceutical company with a singular focus on tesetaxel, which has completed Phase-II studies in metastatic breast cancer. The company's strategy involves advancing tesetaxel through clinical development to secure regulatory approval and eventual market entry. No other therapeutic candidates or revenue streams are referenced in the provided business description.

Frequently asked questions about Odonate

7 analysts currently rate the Odonate stock: 0 recommend buying, 4 holding and 3 selling.

Converted at the current exchange rate, the Odonate share trades at 45,537.38 EUR (50,000.00 USD).

The Odonate share (ODTC) is listed on 5 stock exchanges, including: NASDAQ (ODT), Frankfurt (4OD.F), München (4OD.MU).

The revenue cannot currently be calculated for Odonate.

The profit cannot currently be calculated for Odonate.

The P/E ratio cannot be calculated for Odonate at the moment.

The P/S cannot be calculated for Odonate currently.

The Eulerpool Quality Score for Odonate is 1/10.

The ISIN of Odonate is US6760794031. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Odonate is A2H9FC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Odonate is ODTC. The ticker symbol is used to trade Odonate shares on the stock exchange.

Fair ValueTerminal
41,000.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website odonate.com
Currency
USD
Initial public offering
Dec 7, 2017
ISIN
US6760794031
Cusip
676079106
Sedol
BD1KGM3
Market capitalization
52.65 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.49
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.63 %
Last updated Nov 21, 2026, 3:40 AM

Odonate Peer Group

Odonate Ticker

FRANKFURT · 4OD.FMUNICH · 4OD.MUNASDAQ · ODTOTC · ODTCOTC · ODTC

All fundamentals and in-depth analysis of Odonate

Our stock analysis for Odonate stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Odonate. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.